Skip to content
Evigrade
CriticalAntifungals, triazole derivatives×Class Ia antiarrhythmic (sodium channel blocker with intermediate kinetics)

Updated · Methodology

Mechanism

The liver metabolises quinidine mainly through the enzyme CYP3A4 (quinidine label, US Food and Drug Administration, FDA), and fluconazole moderately inhibits this enzyme (fluconazole summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The pair has not been studied. According to the fluconazole SmPC, fluconazole may inhibit quinidine metabolism, and quinidine prolongs the QT interval and rarely causes torsade de pointes (fluconazole SmPC, AEMPS). Quinidine prolongs the QT interval in a dose-related way, and high blood levels of quinidine raise the risk of torsade de pointes (quinidine FDA label). Fluconazole itself also prolongs the QT interval by directly inhibiting a potassium current in heart cells, and its enzyme inhibition persists for 4–5 days after it is stopped (fluconazole SmPC, AEMPS).

Symptoms

The main risk is QT prolongation and life-threatening polymorphic ventricular tachycardia of the torsade de pointes type (fluconazole summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; quinidine label, US Food and Drug Administration, FDA), which causes palpitations, dizziness and fainting. Other ventricular arrhythmias reported with quinidine are frequent extrasystoles, ventricular tachycardia, ventricular flutter and ventricular fibrillation (quinidine FDA label). Excess quinidine causes vomiting, diarrhoea, tinnitus, high-frequency hearing loss, vertigo, blurred or double vision, photophobia, headache, confusion and delirium. In overdose, the main dangers are ventricular arrhythmias and low blood pressure (quinidine FDA label).

Management

The combination is contraindicated. The Spanish fluconazole summary of product characteristics (SmPC) and the US fluconazole label name quinidine among contraindicated drugs, together with other QT-prolonging drugs that the enzyme CYP3A4 metabolises (fluconazole SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, and label, US Food and Drug Administration, FDA). Fluconazole enzyme inhibition persists for 4–5 days after it is stopped (fluconazole SmPC, AEMPS). Use fluconazole with caution in patients with potentially proarrhythmic conditions. Low potassium and advanced heart failure increase the risk of life-threatening ventricular arrhythmias and torsade de pointes (fluconazole SmPC, AEMPS). With quinidine, the risk of torsade de pointes rises with a slow heart rate, low potassium, magnesium or calcium, and high quinidine levels. According to the US label, the QTc interval on the electrocardiogram (ECG) predicts quinidine-induced ventricular arrhythmias better than blood quinidine levels (quinidine FDA label). In unstable polymorphic ventricular tachycardia, stop quinidine and perform immediate cardioversion or overdrive pacing. Look for low potassium, magnesium and calcium and correct them promptly if possible (quinidine FDA label).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Fluconazole

Other interactions with Quinidine